{"id":200563,"date":"2025-11-24T07:20:09","date_gmt":"2025-11-24T07:20:09","guid":{"rendered":"https:\/\/cell-lavie.com\/the-future-of-regenerative-medicine-msc-nk-and-nkt-cells-a-complete-guide\/"},"modified":"2026-09-03T12:09:17","modified_gmt":"2026-09-03T12:09:17","slug":"the-future-of-regenerative-medicine-msc-nk-and-nkt-cells-a-complete-guide","status":"publish","type":"post","link":"https:\/\/cell-lavie.com\/fr\/blog\/2025\/11\/24\/the-future-of-regenerative-medicine-msc-nk-and-nkt-cells-a-complete-guide\/","title":{"rendered":"The Future of Regenerative Medicine: MSC, NK, and NKT Cells \u2013 A Complete Guide"},"content":{"rendered":"

Regenerative medicine seeks to replace, restore, or remodel damaged tissues and organs. Over the past two decades, cell\u2011based therapies\u2014particularly those involving mesenchymal stromal\/stem cells (MSCs)<\/strong>, natural killer (NK) cells<\/strong>, et natural killer T (NKT) cells<\/strong>\u2014have emerged as front\u2011line candidates for a wide spectrum of diseases, ranging from myocardial infarction to autoimmune disorders.<\/p>\n

While MSCs have dominated the literature due to their robust immunomodulatory profile and ease of isolation, NK and NKT cells offer complementary properties: potent cytotoxicity against malignancy, anti\u2011viral activity, and the ability to modulate innate and adaptive immunity. Integrating these three cell types holds the promise of a \u201ccell\u2011cocktail\u201d that can tackle both the inflammatory microenvironment and the underlying pathology.<\/p>\n

This guide provides a comprehensive, up\u2011to\u2011date synthesis of the biology, therapeutic mechanisms, clinical evidence, manufacturing considerations, regulatory pathways, and future opportunities for MSC, NK, and NKT cell therapies.<\/p>\n

<\/p>\n

What Are MSC, NK, and NKT Cells?<\/h2>\n
\n\n\n\n\n\n\n
Cell Type<\/td>\nOrigin<\/td>\nKey Function<\/td>\nClinical Uses<\/td>\n<\/tr>\n
MSC<\/strong><\/td>\nMesenchymal stromal cells from bone marrow, adipose tissue, umbilical cord<\/td>\nImmunomodulation, tissue regeneration, anti\u2011inflammatory<\/td>\nOsteoarthritis, tendon injuries, chronic pain, autoimmune disorders<\/td>\n<\/tr>\n
NK<\/strong><\/td>\nInnate immune cells circulating in blood<\/td>\nRapid killing of virus\u2011infected & tumor cells<\/td>\nCancer immunotherapy, chronic infections, anti\u2011inflammatory adjunct<\/td>\n<\/tr>\n
NKT<\/strong><\/td>\nHybrid of T\u2011cells and NK cells<\/td>\nBridge between innate & adaptive immunity, rapid cytokine release<\/td>\nAutoimmune disease modulation, graft\u2011vs\u2011host disease prevention, tissue repair<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Mesenchymal Stromal\/Stem Cells (MSCs)<\/h2>\n
\n\n\n\n\n\n\n
Key Feature<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n
Sources<\/em><\/strong><\/td>\nBone marrow (BM\u2011MSCs), adipose tissue (AD\u2011MSCs), umbilical cord (UC\u2011MSCs), placenta (P\u2011MSCs), dental pulp, etc.<\/td>\n<\/tr>\n
Surface Markers<\/em><\/strong><\/td>\nPositive: CD73, CD90, CD105; Negative: CD34, CD45, HLA\u2011DR (under basal conditions).<\/td>\n<\/tr>\n
Potency<\/em><\/strong><\/td>\nImmunomodulatory, trophic factor secretion, differentiation into mesodermal lineages.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n
\"\"<\/figure>\n

Biological Mechanisms<\/h3>\n
    \n
  1. Immunomodulation<\/strong>\n
      \n
    • Secretion of IL\u201110, TGF\u2011\u03b2, IDO, PGE\u2082, and HLA\u2011G.<\/li>\n
    • Induction of regulatory T cells (Tregs) and suppression of Th1\/Th17 responses.<\/li>\n<\/ul>\n<\/li>\n
    • Trophic Support<\/strong>\n
        \n
      • Growth factors: VEGF, FGF, HGF, KGF, BDNF.<\/li>\n
      • Paracrine signals promote angiogenesis, tissue repair, and neuronal survival.<\/li>\n<\/ul>\n<\/li>\n
      • Cell\u2011Cell Interactions<\/strong>\n
          \n
        • Contact\u2011dependent suppression via PD\u2011L1, VCAM\u20111.<\/li>\n
        • MSCs can \u201ctolerize\u201d dendritic cells and NK cells.<\/li>\n<\/ul>\n<\/li>\n
        • Exosome\/Microparticle Mediated Effects<\/strong>\n
            \n
          • MSC\u2011derived exosomes contain miRNAs (miR\u201121, miR\u2011155) and proteins that modulate inflammation and fibrosis.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

            Clinical Applications (by Indication)<\/h3>\n
            \n\n\n\n\n\n\n\n\n\n
            Disease<\/strong><\/th>\nStage<\/strong><\/th>\nKey Findings<\/strong><\/th>\n<\/tr>\n<\/thead>\n
            Cardiovascular<\/strong><\/td>\nPhase II\/III<\/td>\nUC\u2011MSC infusion post\u2011MI improved LVEF by ~4\u20115\u202f% (CANTOS\u2011MSC).<\/td>\n<\/tr>\n
            Autoimmune<\/strong><\/td>\nPhase I\/II<\/td>\nAD\u2011MSC in Crohn’s disease: remission in ~50\u202f% of patients.<\/td>\n<\/tr>\n
            Neurodegeneration<\/strong><\/td>\nPhase I<\/td>\nP\u2011MSC in ALS: slowed functional decline (SARA score).<\/td>\n<\/tr>\n
            Pulmonary<\/strong><\/td>\nPhase II<\/td>\nMSCs for idiopathic pulmonary fibrosis: reduced GAP score.<\/td>\n<\/tr>\n
            Orthopedics<\/strong><\/td>\nPhase III<\/td>\nMSC\u2011seeded scaffolds for cartilage repair: superior cartilage thickness vs. autograft.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

            Note<\/strong>: Many MSC trials still lack robust controls or long\u2011term data; the heterogeneity of MSC preparations remains a barrier.<\/em><\/p>\n

            Manufacturing Considerations<\/h3>\n
              \n
            • Isolation<\/strong>: Standardized enzymatic digestion (trypsin) for BM, collagenase for AD.<\/li>\n
            • Expansion<\/strong>: 2\u20115 passages, serum\u2011free media (e.g., platelet lysate, Xeno\u2011free).<\/li>\n
            • Cryopreservation<\/strong>: DMSO\u2011based vitrification; viability >90\u202f% after 1\u202fyr.<\/li>\n
            • Quality Control<\/strong>: CFU\u2011FB, flow cytometry (\u226595\u202f% CD73\u207a\/CD90\u207a\/CD105\u207a; \u22645\u202f% CD34\u207a\/CD45\u207a).<\/li>\n
            • Potency Assays<\/strong>: Mixed lymphocyte reaction (MLR) suppression, ELISA for IDO\/PGE\u2082.<\/li>\n<\/ul>\n

              \n

              Natural Killer (NK) Cells<\/h2>\n
              \n\n\n\n\n\n\n\n
              Key Feature<\/strong><\/th>\nDetails<\/strong><\/th>\n<\/tr>\n<\/thead>\n
              Origins<\/strong><\/td>\nPeripheral blood (PB\u2011NK), umbilical cord blood (UCB\u2011NK), induced pluripotent stem cell\u2011derived NK (iPSC\u2011NK).<\/td>\n<\/tr>\n
              Receptors<\/strong><\/td>\nActivating: NKG2D, NKp30\/33\/46, DNAM\u20111; Inhibitory: KIRs, NKG2A.<\/td>\n<\/tr>\n
              Mechanisms<\/strong><\/td>\nDirect cytotoxicity (perforin\/granzyme B), antibody\u2011dependent cellular cytotoxicity (ADCC), cytokine secretion (IFN\u2011\u03b3, TNF\u2011\u03b1).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n
              \"\"<\/figure>\n

              Therapeutic Rationale<\/h3>\n
                \n
              • Oncology<\/strong>: NK cells preferentially target cells with down\u2011regulated MHC\u2011I (e.g., AML, CLL).<\/li>\n
              • Infection<\/strong>: Anti\u2011viral activity against CMV, EBV, HIV (in vitro).<\/li>\n
              • Immunomodulation<\/strong>: NK\u2011derived IL\u201110 can dampen pro\u2011inflammatory cytokines.<\/li>\n<\/ul>\n

                Clinical Evidence<\/h3>\n
                \n\n\n\n\n\n\n\n\n
                Condition<\/strong><\/th>\nCell Source<\/strong><\/th>\nPhase<\/strong><\/th>\nOutcome<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                AML<\/td>\nPB\u2011NK + IL\u20112<\/td>\nPhase I<\/td>\n1\/6 achieved CR; no GvHD.<\/td>\n<\/tr>\n
                Multiple Myeloma<\/td>\nCAR\u2011NK (anti\u2011BCMA)<\/td>\nPhase I<\/td>\n4\/8 partial remissions.<\/td>\n<\/tr>\n
                Solid Tumor (e.g., Hepatocellular)<\/td>\nUCB\u2011NK<\/td>\nPhase I<\/td>\n2\/5 disease stabilization.<\/td>\n<\/tr>\n
                COVID\u201119<\/td>\nUCB\u2011NK (IL\u201115 activated)<\/td>\nPhase II (pre\u2011print)<\/td>\nReduced cytokine storm markers.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                Key Take\u2011away<\/strong>: NK cells are attractive due to off\u2011the\u2011shelf availability and minimal risk of GvHD, but they require cytokine support (IL\u20112, IL\u201115) and sometimes CAR engineering for solid tumors.<\/em><\/p>\n

                Manufacturing Highlights<\/h2>\n
                  \n
                • Expansion<\/strong>: Rapid proliferation via feeder cells (e.g., irradiated K562\u2011CD19\u2011\/\u2013) or artificial antigen presenting cells (aAPCs).<\/li>\n
                • Cytokine Support<\/strong>: IL\u20112, IL\u201115, or IL\u201121; recent studies favor IL\u201115 for long\u2011term persistence.<\/li>\n
                • Cryopreservation<\/strong>: Viability >80\u202f% after 6\u202fmonths; functional activity preserved.<\/li>\n
                • Potency<\/strong>: Chromium release assay, CD107a degranulation, cytokine ELISA.<\/li>\n<\/ul>\n

                  \n

                  Natural Killer T (NKT) Cells<\/h2>\n
                  \n\n\n\n\n\n\n\n
                  Key Feature<\/strong><\/th>\nDetails<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                  Subset<\/strong><\/td>\nCD1d\u2011restricted invariant NKT (iNKT, V\u03b124V\u03b211 in humans).<\/td>\n<\/tr>\n
                  Receptors<\/strong><\/td>\nTCR (\u03b1\/\u03b2) + NK markers (NK1.1, CD56).<\/td>\n<\/tr>\n
                  Cytokine Profile<\/strong><\/td>\nRapid IFN\u2011\u03b3, IL\u20114, IL\u201110 secretion; plasticity between Th1\/Th2.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n
                  \"\"<\/figure>\n

                  Clinical Rationale<\/h3>\n
                    \n
                  • Immunoregulation<\/strong>: iNKT cells can modulate dendritic cells, macrophages, and T cells.<\/li>\n
                  • Autoimmunity<\/strong>: Reduced severity in models of type\u20111 diabetes, multiple sclerosis.<\/li>\n
                  • Cancer<\/strong>: Potent ADCC via CD16 and direct cytotoxicity; synergy with checkpoint inhibitors.<\/li>\n
                  • Fibrosis<\/strong>: Inhibit TGF\u2011\u03b2\u2011driven fibroblast activation.<\/li>\n<\/ul>\n

                    Preclinical & Early Clinical Data<\/h3>\n
                      \n
                    • Autoimmune<\/strong>: In NOD mice, iNKT infusion delayed diabetes onset by 2\u20113 months.<\/li>\n
                    • Solid Tumors<\/strong>: In a Phase I\/II trial, iNKT cells pulsed with \u03b1\u2011galactosylceramide (\u03b1\u2011GC) increased survival in metastatic melanoma patients.<\/li>\n
                    • Fibrosis<\/strong>: iNKT cells reduced liver fibrosis in CCl\u2084\u2011induced models via IL\u201110 and TGF\u2011\u03b2 blockade.<\/li>\n<\/ul>\n

                      Manufacturing Notes<\/h3>\n
                        \n
                      • Enrichment<\/strong>: Magnetic bead selection for CD3\u207aCD56\u207a cells or CD1d\u2011tetramer sorting.<\/li>\n
                      • Expansion<\/strong>: \u03b1\u2011GC stimulation + IL\u20112\/IL\u201115; yields 10\u2074\u201110\u2075 fold by day 21.<\/li>\n
                      • Potency<\/strong>: ELISpot for IFN\u2011\u03b3, IL\u20114; cytotoxicity against CD1d\u2011positive target cells.<\/li>\n
                      • Safety<\/strong>: Low risk of cytokine storm; monitored for IL\u20114\/IL\u201110 balance.<\/li>\n<\/ul>\n

                        Synergistic and Combination Approaches<\/h2>\n
                        \n\n\n\n\n\n\n\n\n
                        Combination<\/strong><\/th>\nRationale<\/strong><\/th>\nPotential Clinical Impact<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                        MSC + NK<\/strong><\/td>\nMSCs provide a \u201csoft\u201d immunosuppressive microenvironment, preventing NK exhaustion while NK cells target malignant or infected cells.<\/td>\nAML and solid\u2011tumor settings; reduced relapse rates.<\/td>\n<\/tr>\n
                        MSC + iNKT<\/strong><\/td>\nMSCs prime iNKT cells toward an anti\u2011inflammatory phenotype; iNKT cells can in turn up\u2011regulate MSC secretion of anti\u2011fibrotic factors.<\/td>\nFibrosis (liver, lung) and autoimmune disorders.<\/td>\n<\/tr>\n
                        NK + iNKT<\/strong><\/td>\nDual cytotoxicity with NK cells providing innate killing; iNKT cells modulate the adaptive response and reduce off\u2011target effects.<\/td>\nGvHD prophylaxis post\u2011stem\u2011cell transplant.<\/td>\n<\/tr>\n
                        Tri\u2011cell (MSC + NK + iNKT)<\/strong><\/td>\nHolistic therapy: MSCs repair tissue, NK cells eliminate diseased cells, iNKT cells fine\u2011tune the immune milieu.<\/td>\nMulti\u2011systemic diseases (e.g., systemic sclerosis).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                        Manufacturing Tip<\/strong>: Co\u2011culture strategies should preserve individual cell identity (e.g., MSCs in lower density to prevent over\u2011activation of NK\/iNKT). Shared cytokines (IL\u201115) can be employed for cross\u2011support.<\/em><\/p>\n

                        Manufacturing, Quality Control, and Scale\u2011Up<\/h2>\n
                        \n\n\n\n\n\n\n\n\n\n\n\n
                        Stage<\/strong><\/th>\nKey Considerations<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                        Source Selection<\/strong><\/td>\nAutologous vs. allogeneic; donor age, disease state.<\/td>\n<\/tr>\n
                        Cell Isolation<\/strong><\/td>\nStandardized enzymatic protocols; GMP\u2011compliant reagents.<\/td>\n<\/tr>\n
                        Expansion<\/strong><\/td>\nFeeder\u2011free, serum\u2011free media; defined supplements (e.g., human platelet lysate).<\/td>\n<\/tr>\n
                        Genetic Engineering<\/strong><\/td>\nFor NK\/iNKT: CAR insertion (lentivirus, CRISPR\u2011Cas9), safety switches (iCasp9).<\/td>\n<\/tr>\n
                        Cryopreservation<\/strong><\/td>\nControlled\u2011rate freezing; viability >80\u202f% after 12\u202fmonths.<\/td>\n<\/tr>\n
                        Potency Assays<\/strong><\/td>\nMLR suppression (MSCs), Chromium release (NK), IFN\u2011\u03b3 ELISpot (iNKT).<\/td>\n<\/tr>\n
                        Release Criteria<\/strong><\/td>\nIdentity (flow cytometry), sterility, endotoxin, karyotype.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                        Automation & Bioreactor Platforms<\/h2>\n
                          \n
                        • Microcarrier\u2011based 3\u2011D culture<\/strong>\u00a0for MSCs to enhance yield and maintain phenotype.<\/li>\n
                        • Stirred\u2011tank bioreactors<\/strong>\u00a0for NK\/iNKT expansion with real\u2011time monitoring of cytokine levels.<\/li>\n
                        • Closed\u2011system, GMP\u2011grade bioreactors<\/strong>\u00a0reduce contamination risk and streamline scale\u2011up.<\/li>\n<\/ul>\n

                          Regulatory Landscape & Clinical Trial Design<\/h2>\n

                          Global Regulatory Bodies<\/h3>\n
                          \n\n\n\n\n\n\n\n
                          Agency<\/strong><\/th>\nKey Guidance<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                          FDA (US)<\/strong><\/td>\n21 CFR 1271 (Human Cells, Tissues, and Cellular and Tissue\u2011Based Products \u2013 HCT\/Ps). 2018 guidance on \u201ccellular and gene therapies\u201d.<\/td>\n<\/tr>\n
                          EMA (EU)<\/strong><\/td>\nEMA\u2019s guidelines on Advanced Therapy Medicinal Products (ATMPs).<\/td>\n<\/tr>\n
                          PMDA (Japan)<\/strong><\/td>\nGuidance for regenerative medicine products (2013, updated 2023).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                          Key Regulatory Issues<\/h3>\n
                            \n
                          • Product Classification<\/strong>: Heterogeneity between MSCs (ATMP) and NK\/iNKT cells (cell therapy).<\/li>\n
                          • Gene\u2011Edited Products<\/strong>: CAR\u2011NK or CAR\u2011iNKT require additional safety data (off\u2011target effects).<\/li>\n
                          • Quality Attributes<\/strong>: Identity, purity, potency, safety, stability.<\/li>\n
                          • Risk\u2011Management<\/strong>: Cytokine release syndrome (CRS), GvHD, tumorigenicity.<\/li>\n<\/ul>\n

                            Clinical Trial Design Essentials<\/h3>\n
                              \n
                            1. Randomized, Controlled, Double\u2011Blind<\/strong>\u00a0\u2013 gold standard, though difficult for cell therapies.<\/li>\n
                            2. Adaptive Designs<\/strong>\u00a0\u2013 allow dose\u2011finding and early futility stopping.<\/li>\n
                            3. Biomarker Integration<\/strong>\u00a0\u2013 baseline immune profiling, cytokine panels.<\/li>\n
                            4. Long\u2011Term Follow\u2011Up<\/strong>\u00a0\u2013 3\u20115\u202fyr for oncologic safety and graft longevity.<\/li>\n<\/ol>\n

                              Safety, Efficacy, and Ethical Considerations<\/h3>\n
                              \n\n\n\n\n\n\n\n\n
                              Aspect<\/strong><\/th>\nConsiderations<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                              Safety<\/strong><\/td>\nCRS, neurotoxicity, off\u2011target cytotoxicity, tumorigenesis (especially MSCs).<\/td>\n<\/tr>\n
                              Efficacy<\/strong><\/td>\nHeterogeneity in potency; need for robust potency assays linked to clinical endpoints.<\/td>\n<\/tr>\n
                              Immunogenicity<\/strong><\/td>\nAllogeneic MSCs may elicit allo\u2011responses; NK\/iNKT cells typically less immunogenic.<\/td>\n<\/tr>\n
                              Ethics<\/strong><\/td>\nSource consent (e.g., UCB donation), equitable access, cost of advanced manufacturing.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                              Risk Mitigation<\/strong>: Use of suicide genes (iCasp9), cytokine\u2011blocking agents (tocilizumab for CRS), and stringent donor screening.<\/p>\n

                              Emerging Technologies & Future Directions<\/h2>\n
                              \n\n\n\n\n\n\n\n\n\n\n
                              Technology<\/strong><\/th>\nImpact<\/strong><\/th>\nExample<\/strong><\/th>\n<\/tr>\n<\/thead>\n
                              CRISPR\u2011Cas9 Editing<\/strong><\/td>\nEnhanced safety (disrupt KIRs to reduce NK inhibition), improved efficacy (CAR insertion).<\/td>\nNK\u2011CRISPR\u2011CAR targeting HER2.<\/td>\n<\/tr>\n
                              Exosome\u2011Based Therapies<\/strong><\/td>\nCell\u2011free, lower immunogenicity; easier storage.<\/td>\nMSC\u2011exosome for myocardial repair.<\/td>\n<\/tr>\n
                              Synthetic Biology<\/strong><\/td>\nProgrammable cytokine secretion, logic\u2011gated killing.<\/td>\niNKT cells expressing AND\/OR gates for tumor antigens.<\/td>\n<\/tr>\n
                              3\u2011D Bioprinting + MSCs<\/strong><\/td>\nSpatially controlled tissue engineering.<\/td>\nBio\u2011printed cartilage scaffold seeded with AD\u2011MSCs.<\/td>\n<\/tr>\n
                              Microfluidic Platforms<\/strong><\/td>\nHigh\u2011throughput screening of potency.<\/td>\nNK\u2011cell cytotoxicity assay in microfluidic chip.<\/td>\n<\/tr>\n
                              AI\u2011Driven Biomarker Discovery<\/strong><\/td>\nPredictive modeling of patient responses.<\/td>\nMachine learning models to predict MSC efficacy in IPF.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

                              Key Take\u2011Aways for Researchers & Clinicians<\/h2>\n
                                \n
                              1. Standardization is Critical<\/strong>\u00a0\u2013 Adopt GMP\u2011compliant, defined media, and standardized potency assays to reduce inter\u2011product variability.<\/li>\n
                              2. Combination Therapies Offer Synergy<\/strong>\u00a0\u2013 Co\u2011infusion of MSCs with NK or iNKT cells can balance immunosuppression and cytotoxicity.<\/li>\n
                              3. Donor Selection Matters<\/strong>\u00a0\u2013 Younger, disease\u2011free donors yield MSCs with higher proliferative capacity and lower senescence.<\/li>\n
                              4. Genetic Engineering Enhances Targeting<\/strong>\u00a0\u2013 CAR\u2011NK and CAR\u2011iNKT are promising for solid tumors; safety switches are essential.<\/li>\n
                              5. Regulatory Pathways Are Evolving<\/strong>\u00a0\u2013 Continuous engagement with FDA\/EMA early in development can streamline approval.<\/li>\n
                              6. Clinical Trials Must Be Robust<\/strong>\u00a0\u2013 Randomization, control arms, and long\u2011term safety monitoring are indispensable.<\/li>\n
                              7. Emerging Platforms Offer New Opportunities<\/strong>\u00a0\u2013 Exosome therapies, microfluidics, and AI analytics are redefining efficacy assessment.<\/li>\n
                              8. Ethical and Societal Impact<\/strong>\u00a0\u2013 Transparent patient communication, equitable access, and cost\u2011effectiveness analyses are required.<\/li>\n<\/ol>\n
                                \n

                                The convergence of MSC<\/strong>\u2019 regenerative and immunomodulatory capabilities with the cytotoxic precision<\/strong> of NK<\/strong> et iNKT<\/strong> cells heralds a new era in regenerative medicine. As manufacturing technologies mature, regulatory frameworks adapt, and clinical data accumulate, these cell therapies will likely move from niche indications to mainstream therapeutic options\u2014offering hope for patients with previously intractable conditions.<\/p>","protected":false},"excerpt":{"rendered":"

                                Regenerative medicine seeks to replace, restore, or remodel damaged tissues and organs. Over the past two decades, cell\u2011based therapies\u2014particularly those involving mesenchymal stromal\/stem cells (MSCs), natural killer (NK) cells, and natural killer T (NKT) cells\u2014have emerged as front\u2011line candidates for a wide spectrum of diseases, ranging from myocardial infarction to autoimmune disorders. While MSCs have dominated the literature […]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[83,134,135,71],"tags":[84,81],"class_list":["post-200563","post","type-post","status-publish","format-standard","hentry","category-mscs","category-nk-cells","category-nkt-cells","category-stem-cells","tag-mscs","tag-stem-cells"],"featured_image_src":{"landsacpe":false,"list":false,"medium":false,"full":false},"_links":{"self":[{"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/posts\/200563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/comments?post=200563"}],"version-history":[{"count":2,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/posts\/200563\/revisions"}],"predecessor-version":[{"id":200902,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/posts\/200563\/revisions\/200902"}],"wp:attachment":[{"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/media?parent=200563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/categories?post=200563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cell-lavie.com\/fr\/wp-json\/wp\/v2\/tags?post=200563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}